Literature DB >> 23771405

Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate.

Guillaume Fond1, Alexandra Macgregor, Ryad Tamouza, Nora Hamdani, Alexandre Meary, Marion Leboyer, Jean-Francois Dubremetz.   

Abstract

Recent studies have shown a strong link between Toxoplasma gondii infection and psychiatric disorders, especially schizophrenia and bipolar disorders (odd ratio ≈2.7 for each disorder). Antipsychotic drugs and mood stabilizers may have anti-toxoplasmic activity that potentially may be associated with better effectiveness in these disorders, but previous results have been few in number and conflicting. We therefore sought to determine which daily prescribed antipsychotics and mood stabilizer have the best anti-toxoplasmic activity during the development phase of the parasite. In the present study, we examined the effects of commonly used antipsychotic drugs (amisulpride, cyamemazine, fluphenazine, haloperidol, levomepromazine, loxapine, olanzapine, risperidone and tiapride) and one mood-stabilizing agent (valproate) on toxoplasmic activity. We replicated that fluphenazine has a high anti-toxoplasmic activity, but it does not seem to be a phenothiazine-specific class effect: indeed, we found that another first-generation antipsychotic, zuclopenthixol, has a high anti-toxoplasmic activity. Valproate, tiapride and amisulpride have no anti-toxoplasmic activity on parasite growth, and the other antipsychotic drugs showed low or intermediate anti-toxoplasmic activity. As it is not possible to know the intracellular concentrations of antipsychotics in the brain, further clinical studies are warranted to determine whether these in vitro findings have potential implications in treatment of toxo-positive patients with schizophrenia. These findings may be potentially relevant for the choice of the first-line antipsychotic drug or mood stabilizer in previously infected patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23771405     DOI: 10.1007/s00406-013-0413-4

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  29 in total

1.  Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach.

Authors:  H Kirchherr; W N Kühn-Velten
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-06-23       Impact factor: 3.205

2.  Effects of toxoplasma on human behavior.

Authors:  Jaroslav Flegr
Journal:  Schizophr Bull       Date:  2007-01-11       Impact factor: 9.306

3.  Evaluation of five antischizophrenic agents against Toxoplasma gondii in human cell cultures.

Authors:  David G Goodwin; Jeannine S Strobl; David S Lindsay
Journal:  J Parasitol       Date:  2010-09-14       Impact factor: 1.276

4.  The role of dopamine in Toxoplasma-induced behavioural alterations in mice: an ethological and ethopharmacological study.

Authors:  A Skallová; P Kodym; D Frynta; J Flegr
Journal:  Parasitology       Date:  2006-08-02       Impact factor: 3.234

5.  Relationship between Toxoplasma gondii infection and bipolar disorder in a French sample.

Authors:  Nora Hamdani; Claire Daban-Huard; Mohamed Lajnef; Jean-Romain Richard; Marine Delavest; Ophélia Godin; Emmanuel Le Guen; François-Eric Vederine; Jean-Pierre Lépine; Stéphane Jamain; Josselin Houenou; Philippe Le Corvoisier; Masayuki Aoki; Helene Moins-Teisserenc; Dominique Charron; Rajagopal Krishnamoorthy; Robert Yolken; Faith Dickerson; Ryad Tamouza; Marion Leboyer
Journal:  J Affect Disord       Date:  2012-12-27       Impact factor: 4.839

Review 6.  Maternal infection and schizophrenia: implications for prevention.

Authors:  Alan S Brown; Paul H Patterson
Journal:  Schizophr Bull       Date:  2010-12-06       Impact factor: 9.306

7.  A controlled prospective study of toxoplasma gondii infection in individuals with schizophrenia: beyond seroprevalence.

Authors:  Dunja Hinze-Selch; Walter Däubener; Lena Eggert; Sükran Erdag; Renate Stoltenberg; Sibylle Wilms
Journal:  Schizophr Bull       Date:  2007-03-26       Impact factor: 9.306

Review 8.  [Toxoplasma gondii: a potential role in the genesis of psychiatric disorders].

Authors:  G Fond; D Capdevielle; A Macgregor; J Attal; A Larue; M Brittner; D Ducasse; J-P Boulenger
Journal:  Encephale       Date:  2012-08-21       Impact factor: 1.291

9.  The neurotropic parasite Toxoplasma gondii increases dopamine metabolism.

Authors:  Emese Prandovszky; Elizabeth Gaskell; Heather Martin; J P Dubey; Joanne P Webster; Glenn A McConkey
Journal:  PLoS One       Date:  2011-09-21       Impact factor: 3.240

Review 10.  Toxoplasma gondii and schizophrenia.

Authors:  E Fuller Torrey; Robert H Yolken
Journal:  Emerg Infect Dis       Date:  2003-11       Impact factor: 6.883

View more
  20 in total

1.  Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach.

Authors:  Douglas M Ruderfer; Alexander W Charney; Ben Readhead; Brian A Kidd; Anna K Kähler; Paul J Kenny; Michael J Keiser; Jennifer L Moran; Christina M Hultman; Stuart A Scott; Patrick F Sullivan; Shaun M Purcell; Joel T Dudley; Pamela Sklar
Journal:  Lancet Psychiatry       Date:  2016-02-23       Impact factor: 27.083

Review 2.  Toxoplasma gondii and schizophrenia: a review of published RCTs.

Authors:  Sam D Chorlton
Journal:  Parasitol Res       Date:  2017-05-15       Impact factor: 2.289

3.  Recurrent headaches may be caused by cerebral toxoplasmosis.

Authors:  Joseph Prandota; Anna Gryglas; Aleksander Fuglewicz; Agata Zesławska-Faleńczyk; Barbara Ujma-Czapska; Leszek Szenborn; Janusz Mierzwa
Journal:  World J Clin Pediatr       Date:  2014-08-08

4.  The new risk variant CACNA1C and brain circuits in schizophrenia.

Authors:  Andrea Schmitt; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-03       Impact factor: 5.270

5.  Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort.

Authors:  G Fond; N Resseguier; F Schürhoff; O Godin; M Andrianarisoa; L Brunel; E Bulzacka; B Aouizerate; F Berna; D Capdevielle; I Chereau; T D'Amato; C Dubertret; J Dubreucq; C Faget; F Gabayet; C Lançon; P M Llorca; J Mallet; D Misdrahi; C Passerieux; R Rey; A Schandrin; M Urbach; P Vidailhet; L Boyer; M Leboyer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-11-10       Impact factor: 5.270

Review 6.  Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity.

Authors:  Andrew J Neville; Sydney J Zach; Xiaofang Wang; Joshua J Larson; Abigail K Judge; Lisa A Davis; Jonathan L Vennerstrom; Paul H Davis
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

7.  Downregulation of the Central Noradrenergic System by Toxoplasma gondii Infection.

Authors:  Isra Alsaady; Ellen Tedford; Mohammad Alsaad; Greg Bristow; Shivali Kohli; Matthew Murray; Matthew Reeves; M S Vijayabaskar; Steven J Clapcote; Jonathan Wastling; Glenn A McConkey
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

Review 8.  The promise of biological markers for treatment response in first-episode psychosis: a systematic review.

Authors:  Guillaume Fond; Marc-Antoine d'Albis; Stéphane Jamain; Ryad Tamouza; Celso Arango; W Wolfgang Fleischhacker; Birte Glenthøj; Markus Leweke; Shôn Lewis; Phillip McGuire; Andreas Meyer-Lindenberg; Iris E Sommer; Inge Winter-van Rossum; Shitij Kapur; René S Kahn; Dan Rujescu; Marion Leboyer
Journal:  Schizophr Bull       Date:  2015-03-10       Impact factor: 9.306

9.  Valproic Acid Inhibits Chronic Toxoplasma Infection and Associated Brain Inflammation in Mice.

Authors:  Marjan Enshaeieh; Geita Saadatnia; Jalal Babaie; Majid Golkar; Samira Choopani; Mohammad Sayyah
Journal:  Antimicrob Agents Chemother       Date:  2021-08-02       Impact factor: 5.191

10.  Schizophrenia and Bartonella spp. Infection: A Pilot Case-Control Study.

Authors:  Erin Lashnits; Ricardo Maggi; Fredrik Jarskog; Julie Bradley; Edward Breitschwerdt; Flavio Frohlich
Journal:  Vector Borne Zoonotic Dis       Date:  2021-03-15       Impact factor: 2.523

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.